Security
Actuate Therapeutics, Inc. Common stock · ACTU
ACTUNASDAQCommon stockCurrentCIK 1652935Updated Nov 3, 2026
ACTU price & chart
Loading TradingView…
NASDAQ:ACTU on TradingView ↗About the company
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta (“GSK-3β”), a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β, and we believe elraglusib is one of the most advanced GSK-3β inhibitors in clinical development.
In the news
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 17,713,934Source | 14,262,781Source | 5,199,339Source | 6,968,901Source | 1,730,826Source | 8,911,286Source | 4,483,039Source | — | 14,035,910Source | 9,318,448Source | 2,995,566Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,924,763Source | 13,523,449Source | 4,425,841Source | 6,492,656Source | 351,709Source | 8,134,004Source | 3,889,405Source | — | 13,159,423Source | 8,641,622Source | — |
| Assets, CurrentUSD | 17,444,000Source | 14,262,781Source | 4,747,941Source | 6,688,559Source | 549,687Source | 8,519,448Source | 4,248,564Source | — | 13,643,419Source | 9,207,900Source | 2,995,566Source |
| Prepaid Expense and Other Assets, CurrentUSD | 519,237Source | 739,332Source | 322,100Source | 195,903Source | 197,978Source | 385,444Source | 359,159Source | — | 483,996Source | 566,278Source | 36,907Source |
| Other Assets, NoncurrentUSD | 269,934Source | — | 451,398Source | 280,342Source | — | 391,838Source | 234,475Source | — | 392,491Source | 110,548Source | 0Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 6,777,653Source | 8,904,093Source | 4,210,187Source | 9,622,605Source | 21,808,988Source | 5,126,888Source | 9,570,776Source | — | 6,111,907Source | 9,214,262Source | 8,443,675Source |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 23Source | 20Source | 24Source | 20Source | 2Source | 24Source | 20Source | — | 23Source | 20Source | 2Source |
| Additional Paid in CapitalUSD | 160,990,006Source | 131,292,428Source | 166,089,213Source | 141,992,554Source | 5,706,231Source | 164,017,824Source | 133,609,116Source | — | 162,531,681Source | 132,484,015Source | 5,468,006Source |
| Retained Earnings (Accumulated Deficit)USD | -150,053,748Source | -125,933,760Source | -165,100,085Source | -144,646,278Source | -119,962,799Source | -160,233,450Source | -138,696,873Source | — | -154,607,701Source | -132,379,849Source | -105,094,521Source |
| Stockholders' Equity Attributable to ParentUSD | 10,936,281Source | 5,358,688Source | 989,152Source | -2,653,704Source | -114,256,566Source | 3,784,398Source | -5,087,737Source | -107,774,366Source | 7,924,003Source | 104,186Source | -99,626,513Source |
| Liabilities and EquityUSD | 17,713,934Source | 14,262,781Source | 5,199,339Source | 6,968,901Source | 1,730,826Source | 8,911,286Source | 4,483,039Source | — | 14,035,910Source | 9,318,448Source | 2,995,566Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 6,372,662Source | 8,497,410Source | 3,805,196Source | 9,200,721Source | 20,072,998Source | 4,721,897Source | 9,153,954Source | — | 5,706,916Source | 8,802,503Source | 6,920,594Source |
| Accounts Payable, CurrentUSD | 1,245,375Source | 2,330,005Source | 1,076,691Source | 3,171,015Source | 5,893,034Source | 1,201,393Source | 2,644,349Source | — | 1,524,190Source | 1,921,189Source | 3,421,840Source |
| Additional Financial Items | |||||||||||
| Dividends PayableUSD | — | 0Source | — | — | 0Source | — | — | — | — | 0Source | 0Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 1,340,769Source | 1,579,271Source | 1,356,389Source | 1,125,101Source | 6,046,661Source | 1,995,793Source | 423,539Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -322,797Source | 622,162Source | -512,536Source | -1,500,651Source | 1,290,993Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,017,327Source | -4,618,740Source | -19,206,253Source | -21,842,648Source | -21,625,167Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -8,092Source | -133,477Source | 23,724,054Source | 27,525,611Source | 4,134,516Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 16,924,763Source | 13,523,449Source | 4,425,841Source | 6,492,656Source | 8,134,004Source | 3,889,405Source | 13,159,423Source | 8,641,622Source | 2,958,659Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 70,957Source | 71,033Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 800Source | 800Source | 800Source | 800Source | 0Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,800,614Source | 565,981Source | — | 1,579,271Source | — | 1,125,101Source | 6,046,661Source | 1,995,793Source | 423,539Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 4,145,142Source | 5,954,277Source | 7,291,408Source |
| Dividends PayableUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,294,456Source | 1,635,801Source | 2,839,763Source | 3,204,072Source | 3,140,712Source | 3,145,265Source | 12,202,692Source | 6,484,458Source | 3,265,497Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 800Source | 800Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 5,063Source | 3,489Source | 5,063Source | 5,062Source | 5,062Source | 5,063Source | 20,250Source | 18,717Source | 43,641Source |
| Investment Income, InterestUSD | — | — | 69,971Source | 80,747Source | 45,016Source | 24,534Source | 85,269Source | 53,623Source | 287,710Source | 222,293Source | 352,672Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,407,470Source | -5,970,961Source | -4,866,635Source | -5,949,405Source | -5,625,749Source | -6,317,024Source | -22,227,852Source | -27,285,328Source | -24,744,620Source |
| Nonoperating Income (Expense)USD | — | — | 64,908Source | -578,058Source | 39,953Source | 19,472Source | 80,207Source | 48,560Source | 267,460Source | -2,124,594Source | 229,209Source |
| Operating ExpensesUSD | — | — | 5,472,378Source | 5,392,903Source | 4,906,588Source | 5,968,877Source | 5,705,956Source | 6,365,584Source | 22,495,312Source | 25,160,734Source | 24,973,829Source |
| Operating Lease, ExpenseUSD | — | — | 12,900Source | — | 13,100Source | — | 12,900Source | 12,600Source | 51,200Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 519,624Source | 0Source | 3,826,336Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 34,115Source | — | — |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -5,472,378Source | -5,392,903Source | -4,906,588Source | -5,968,877Source | -5,705,956Source | -6,365,584Source | -22,495,312Source | -25,160,734Source | -24,973,829Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 800Source | 800Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,407,470Source | -5,970,961Source | -4,866,635Source | -5,949,405Source | -5,625,749Source | -6,317,024Source | -22,227,852Source | -27,285,328Source | -24,744,620Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.25Source | -0.55Source | -0.2Source | -0.3Source | -0.24Source | -0.32Source | -1.06Source | -3.26Source | -17.24Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.25Source | -0.55Source | -0.2Source | -0.3Source | -0.24Source | -0.32Source | -1.06Source | -3.26Source | -17.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 21,394,965Source | 10,772,640Source | 23,871,850Source | 19,646,475Source | 23,537,134Source | 19,497,731Source | 21,021,817Source | 8,372,741Source | 1,434,964Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 21,394,965Source | 10,772,640Source | 23,871,850Source | 19,646,475Source | 23,537,134Source | 19,497,731Source | 21,021,817Source | 8,372,741Source | 1,434,964Source |
| Interest Expense (non-operating)USD | — | — | 5,063Source | 3,489Source | 5,063Source | 5,062Source | 5,062Source | 5,063Source | 20,250Source | 18,717Source | 43,641Source |
| Additional Financial Items | |||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 800Source | 800Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,294,456Source | 1,635,801Source | 2,839,763Source | 3,204,072Source | 3,140,712Source | 3,145,265Source | 12,202,692Source | 6,484,458Source | 3,265,497Source |
| Investment Income, InterestUSD | — | — | 69,971Source | 80,747Source | 45,016Source | 24,534Source | 85,269Source | 53,623Source | 287,710Source | 222,293Source | 352,672Source |
| Nonoperating Income (Expense)USD | — | — | 64,908Source | -578,058Source | 39,953Source | 19,472Source | 80,207Source | 48,560Source | 267,460Source | -2,124,594Source | 229,209Source |
| Operating ExpensesUSD | — | — | 5,472,378Source | 5,392,903Source | 4,906,588Source | 5,968,877Source | 5,705,956Source | 6,365,584Source | 22,495,312Source | 25,160,734Source | 24,973,829Source |
| Operating Lease, ExpenseUSD | — | — | 12,900Source | — | 13,100Source | — | 12,900Source | 12,600Source | 51,200Source | — | — |
| Research and Development ExpenseUSD | — | — | 2,177,922Source | 3,757,102Source | 2,066,825Source | 2,764,805Source | 2,565,244Source | 3,220,319Source | 10,292,620Source | 18,676,276Source | 21,708,332Source |
Offerings
Registration 333-299332
Registration 333-288952
Registration 333-286201
Filing attachments
actuate_ex107.htm · S-1/A · 2026-10-19
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 ACTUATE THERAPEUTICS, INC. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗actuate_ex107.htm · S-1/A · 2026-10-14
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Actuate Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗actuate_ex107.htm · S-1 · 2026-10-06
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Actuate Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗actuate_ex107.htm · S-8 · 2026-05-14
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 ACTUATE THERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Rule Price Per Unit Equity …
Read attachment ↗actuate_ex107.htm · S-1 · 2025-07-25
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Actuate Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗actuate_ex107.htm · S-1 · 2025-03-28
EX-FILING FEES 5 actuate_ex107.htm CALCULATION OF FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Actuate Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum Fee Amount Carry Carr…
Read attachment ↗